Starpharma Rendement en dividendes
Quel est le Rendement en dividendes de Starpharma?
Le Rendement en dividendes de Starpharma Holdings Limited est 0.00%
Quelle est la définition de Rendement en dividendes?
Le rendement en dividendes représente le rapport entre les dividendes versés aux actionnaires par action et le prix du marché par action pour la dernière année.
The dividend yield or dividend-price ratio of a share is the dividend per share, divided by the price per share. It is also a company's total annual dividend payments divided by its market capitalization, assuming the number of shares is constant, and is often expressed as a percentage. The reciprocal of the dividend yield is the price-dividend ratio.
A higher dividend yield has been considered to be desirable among many investors. A high dividend yield can be considered to be evidence that a stock is underpriced or that the company has fallen on hard times and future dividends will not be as high as previous ones. Similarly a low dividend yield can be considered evidence that the stock is overpriced or that future dividends might be higher. Some investors may find a higher dividend yield attractive, for instance as an aid to marketing a fund to retail investors, or maybe because they cannot get their hands on the capital, which may be tied up in a trust arrangement. In contrast some investors may find a higher dividend yield unattractive, perhaps because it increases their tax bill.
Rendement en dividendes des entreprises dans Health Care secteur sur ASX par rapport à Starpharma
Que fait Starpharma?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Entreprises avec rendement en dividendes similaire à Starpharma
- Starpharma a Rendement en dividendes de 0.00%
- The Monks Investment Trust Plc a Rendement en dividendes de 0.00%
- Crestwood Equity Partners LP a Rendement en dividendes de 0.00%
- Veritas (India) a Rendement en dividendes de 0.00%
- Pacific Horizon Investment Trust Plc a Rendement en dividendes de 0.01%
- AVI Global Trust plc a Rendement en dividendes de 0.01%
- Artemis Alpha Trust plc a Rendement en dividendes de 0.01%